193 related articles for article (PubMed ID: 15708273)
1. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
2. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
4. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
6. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Fleischer G; Dörr W
Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
[TBL] [Abstract][Full Text] [Related]
8. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
9. Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
Mangoni M; Yue X; Morin C; Violot D; Frascogna V; Tao Y; Opolon P; Castaing M; Auperin A; Biti G; Barritault D; Vozenin-Brotons MC; Deutsch E; Bourhis J
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1242-50. PubMed ID: 19545790
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
11. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Soref CM; Hacker TA; Fahl WE
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e701-7. PubMed ID: 22330992
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.
Feng M; Smith DE; Normolle DP; Knol JA; Pan CC; Ben-Josef E; Lu Z; Feng MR; Chen J; Ensminger W; Lawrence TS
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1441-7. PubMed ID: 22440042
[TBL] [Abstract][Full Text] [Related]
13. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation.
Geng L; Hanson WR; Malkinson FD
Int J Radiat Biol; 1992 Apr; 61(4):533-7. PubMed ID: 1349335
[TBL] [Abstract][Full Text] [Related]
14. Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Clémenson C; Liu W; Bricout D; Soyez-Herkert L; Chargari C; Mondini M; Haddad R; Wang-Zhang X; Benel L; Bloy C; Deutsch E
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1141-1152. PubMed ID: 31063799
[TBL] [Abstract][Full Text] [Related]
15. Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.
Varghese JJ; Schmale IL; Mickelsen D; Hansen ME; Newlands SD; Benoit DSW; Korshunov VA; Ovitt CE
J Dent Res; 2018 Oct; 97(11):1252-1259. PubMed ID: 29634396
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
Bourhis J; De Crevoisier R; Abdulkarim B; Deutsch E; Lusinchi A; Luboinski B; Wibault P; Eschwege F
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1105-8. PubMed ID: 10725619
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
[TBL] [Abstract][Full Text] [Related]
19. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
20. Amifostine in clinical oncology: current use and future applications.
Koukourakis MI
Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
